Oprah Winfrey-Backed Wellness Stock Stumbles As GLP-1 Boom Reshapes Consumer Habits: Growth Score Plummets - WW International ( NASDAQ:WW )
Prominent weight-loss and wellness company, WW International Inc. ( NASDAQ:WW ) , backed by renowned talk show host Oprah Winfrey, has seen better days, with the company filing for bankruptcy early this year, and continuing to teeter on the edge after relisting on the Nasdaq.
Pfizer's CEO Sends a Warning to Eli Lilly. Is the Stock a Buy?
Pfizer's weight management pipeline just got a boost.
Consumer Brands Shake Things Up...With Mergers
2025 has been quite the year for consumer brands, but not in a good way. The industry has underperformed for the past three years and many of the world's largest consumer brand companies are resorting to mergers & acquisitions, asset sales, and spin-offs to rejuvenate their prospects.
NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?
Novo Nordisk stock falls 10% in three months as guidance cuts, GLP-1 rivalry and looming U.S. price resets cloud growth and elevate execution risks.
Here is What to Know Beyond Why Eli Lilly and Company ( LLY ) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ
Eli Lilly's surging GLP-1 momentum and Johnson & Johnson's diversified strength set up a compelling 2025 showdown for investors weighing growth vs. stability.
This Sector Is Suddenly Crushing the Broader Market. Should You Invest $1,000?
Healthcare stocks have far outperformed the broader market over the past month.
Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare Giants' Stocks?
Investors will be watching what Trump makes happen.
Prediction: This Will Be Wall Street's Next Trillion-Dollar Stock
Drugs for weight loss and diabetes are taking Eli Lilly to new heights.
Druckenmiller Q3: Opens Position in Amazon, Closes Microsoft - Amazon.com ( NASDAQ:AMZN )
Stanley Druckenmiller's Duquesne Family Office filed its third-quarter 13F on Friday and revealed a dynamic and actively managed portfolio, reinforcing the firm's reputation for agile and opportunity-driven asset allocation. GOOGL stock is moving. See all the details here.
Government Reopens, AI Stocks Slide On Supply Crunch Fears - CoreWeave ( NASDAQ:CRWV ) , General Motors ( NYSE:GM )
After the longest shutdown on record, the U.S. government has reopened and federal agencies are rushing to publish a backlog of delayed economic data. Yet the administration warned that key indicators - most notably October jobs and inflation figures - may be permanently compromised, due to a ...
Ozempic Maker Novo Nordisk Faces Board Shakeup - Novo Nordisk ( NYSE:NVO )
On Friday, Novo Nordisk A/S' ( NYSE:NVO ) board director Mikael Dolsten said he will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025.
Can Lilly's Next-Gen Obesity Drugs Help Sustain Its Market Dominance?
Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing weight-loss market.
Pharma ETFs in Spotlight Following Robust Q3 Earnings Results
Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.
Zacks Investment Ideas feature highlights: IWM, CoreWeave, Astera Labs, Nebius, Expand Energy, Eli Lilly and Nvidia
Zacks Investment Ideas tracks market shifts as IWM strength, AI stock rotation and Nvidia's key support test shape year-end positioning.
Can Equities Stabilize after the Government Reopens?
As traders position for year-end, the government shutdown is over, major market indices are filling gaps, and seasonal momentum looms.
Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month
As National Alzheimer's Awareness Month spotlights new treatments, healthcare ETFs like XLV and VHT might gain fresh investor appeal.
Here Are the Top Growth Healthcare Stocks Every New Investor Should Know
These top growth stocks have plenty of room left to run.
2 Quality Healthcare Stocks That Could Build a Strong Foundation for Beginner Investors
Healthcare stocks have plenty to offer new investors.
1 Incredible Reason to Buy LLY's Stock in November
Eli Lilly struck a deal with President Donald Trump last week that could send the stock much higher.
Dow Jones Hits Record Highs, AMD Jumps: Markets Today - Albemarle ( NYSE:ALB ) , Advanced Micro Devices ( NASDAQ:AMD )
U.S. blue-chip stocks climbed again on Wednesday, extending their winning streak to a fourth straight session and sending the Dow Jones index to record territory. The move underscored renewed investor appetite for old-economy leaders outside the red-hot AI trade.
How Much Did Skyrizi and Rinvoq Drive AbbVie's Q3 Performance?
ABBV's growth engine keeps humming as Skyrizi and Rinvoq together now power more than 40% of total revenues and drive new market share gains.
Company News for Nov 12, 2025
Companies in The News Are: SONY, SE, ...
Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence ( AI ) Stock
Recursion is about to go toe-to-toe with the largest healthcare company.
$100 Invested In Eli Lilly 10 Years Ago Would Be Worth This Much Today - Eli Lilly ( NYSE:LLY )
Eli Lilly ( NYSE:LLY ) has outperformed the market over the past 10 years by 15.62% on an annualized basis producing an average annual return of 28.38%. Currently, Eli Lilly has a market capitalization of $890.10 billion.
Eli Lilly Drops CVS Health's Drug Benefit Plan For Employees Ahead Of 2026 Switch - CVS Health ( NYSE:CVS ) , Eli Lilly ( NYSE:LLY )
Eli Lilly & Co. ( NYSE:LLY ) is reportedly dropping CVS Health Inc.'s ( NYSE:CVS ) drug benefit plan for its employees.
Can NVO's Ozempic, Wegovy Sales Improve in 2026 After a Subdued Q3?
Novo Nordisk eyes a 2026 comeback as it slashes jobs, cuts U.S. semaglutide prices and focuses on expanding the reach of key drugs after a weak Q3.
Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' - CVS Health ( NYSE:CVS ) , Cigna Group ( NYSE:CI )
Dave Ricks, CEO of pharmaceutical giant Eli Lilly and Co. ( NYSE:LLY ) , delivered a scathing critique of pharmacy benefit managers ( PBMs ) , accusing the industry's "middle actors" of "rent taking" and creating a "terrible incentive" structure that caused insulin list prices to skyrocket.
This Unstoppable Growth Stock Just Delivered More Good News: Time to Buy?
This drugmaker's innovation engine continues to operate at full capacity.
Three Healthcare Buys That Wall Street Loves
These three healthcare stocks are outperforming most of the sector.
Lilly Up 18% in a Month: Should You Buy, Sell or Hold the Stock?
Eli Lilly stock jumps 18% in a month as strong Q3 results, upgraded guidance and rising demand for Mounjaro and Zepbound fuel investor optimism.
Is Invesco Pharmaceuticals ETF ( PJP ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?
Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs.
Here's How Much $100 Invested In Eli Lilly 15 Years Ago Would Be Worth Today - Eli Lilly ( NYSE:LLY )
Eli Lilly ( NYSE:LLY ) has outperformed the market over the past 15 years by 12.52% on an annualized basis producing an average annual return of 24.91%. Currently, Eli Lilly has a market capitalization of $866.23 billion.
Eli Lilly Stock Surges As Analyst Sees More Room To Run - Eli Lilly ( NYSE:LLY )
Eli Lilly And Company ( NYSE:LLY ) shares are trading higher Monday after Leerink Partners upgraded the stock to an Outperform rating and raised its price target to $1,104. LLY is testing upper boundaries. See what is happening here.
Will Lower GLP-1 Prices Undermine Novo Nordisk's Near-Term Outlook?
NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.
Pfizer Wins Obesity War Against NVO, to Buy Metsera for Around $10B
Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.
Eli Lilly Expands Genetic Eye-Disease Focused Pipeline With MeiraGTx Gene Therapy Collaboration - Eli Lilly ( NYSE:LLY ) , MeiraGTx Hldgs ( NASDAQ:MGTX )
MeiraGTx Holdings plc ( NASDAQ:MGTX ) stock is trading higher after the company inked a strategic collaboration in the area of ophthalmology with Eli Lilly and Co. ( NYSE:LLY ) .
Zscaler To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Monday - Genmab ( NASDAQ:GMAB ) , HubSpot ( NYSE:HUBS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler cut SITE Centers Corp. ( NYSE:SITE ) price target from $12 to $10.
Does Trump's MFN Policy Put Pharma ETFs in the Crosshairs?
With Trump's MFN policy cutting U.S. drug prices, will Pharma ETFs such as IHE, heavily weighted toward Eli Lilly and Novo Nordisk, lose momentum?
This Eli Lilly Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Array Technologies ( NASDAQ:ARRY ) , Eli Lilly ( NYSE:LLY )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
3 Fantastic Growth Opportunities for Eli Lilly That Go Beyond GLP-1 Drugs
For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades.
Huge News for Eli Lilly Stock and Novo Nordisk Stock Investors as Companies Make Deal With Trump
The companies announced a huge deal that will have implications for investors.
This Unstoppable Growth Stock Just Gave Investors More Reasons to Buy
The stock didn't stay down for too long.
Prediction: Eli Lilly Will Be Worth More Than Berkshire Hathaway by 2030
It could become the first trillion-dollar pharmaceutical company in the process.
Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for Investors.
Weight loss drugs generated about $10 billion for Lilly in the most recent quarter.
Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance - Metsera ( NASDAQ:MTSR ) , Eli Lilly ( NYSE:LLY )
Pfizer Inc. ( NYSE:PFE ) secured a $10 billion deal to acquire obesity drug developer Metsera, Inc. ( NASDAQ:MTSR ) , beating out Novo Nordisk A/S ( NYSE:NVO ) after a heated bidding war that captivated Wall Street.
Why Novo Nordisk Stock Is Sinking This Week
The global drugmaker is facing some headwinds related to tough competition.
Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment - Eli Lilly ( NYSE:LLY )
On Thursday, Eli Lilly and Co. ( NYSE:LLY ) released data from a Phase 2 trial evaluating the safety and efficacy of eloralintide, an investigational once-weekly, selective amylin receptor agonist, in 263 obese adults with at least one obesity-related health issue and without type 2 diabetes.
LLY's GLP-1 Duo Boosts Sales Amid Rising Demand for Obesity Drugs
Lilly's Mounjaro and Zepbound continue to power growth as new launches boost momentum amid rising obesity competition.
